BDF
NVO

Balasa Dinverno & Foltz’s Novo Nordisk NVO Stock Holding History

Balasa Dinverno & Foltz’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$316K Buy
6,338
+60
+1% +$3.21K 0.02% 264
2022
Q2 		$350K Buy
6,278
+58
+0.9% +$3.22K 0.02% 244
2022
Q1 		$345K Sell
6,220
-126
-2% -$6.47K 0.02% 246
2021
Q4 		$355K Buy
6,346
+126
+2% +$6.83K 0.02% 242
2021
Q3 		$299K Buy
6,220
+218
+4% +$10.5K 0.02% 256
2021
Q2 		$251K Buy
+6,002
New +$233K 0.02% 289

Other funds holding NVO

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Balasa Dinverno & Foltz's NVO Position: Q3 2022 in Review

Balasa Dinverno & Foltz increased its Novo Nordisk (NVO) stake by 0.96% in Q3 2022, buying an estimated $3.21K and bringing the position to 6,338 shares worth $316K. The position accounts for 0.02% of the portfolio, ranked #264.

Balasa Dinverno & Foltz first reported a position in NVO in Q2 2021 and has held it in 6 quarters since. The position peaked at $355K in Q4 2021. 907 funds tracked by Wall St. Rank hold NVO as of Q3 2022.

  • Balasa Dinverno & Foltz held 6,338 shares of Novo Nordisk worth $316K as of Q3 2022.
  • Balasa Dinverno & Foltz bought 60 Novo Nordisk shares in Q3 2022, an estimated $3.21K.
  • Novo Nordisk made up 0.02% of Balasa Dinverno & Foltz's portfolio in Q3 2022, its #264 holding.
  • Balasa Dinverno & Foltz first reported a position in Novo Nordisk in Q2 2021 and has held it in 6 quarters since.
  • Balasa Dinverno & Foltz's Novo Nordisk position peaked at $355K in Q4 2021.
  • 907 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2022.

Based on Balasa Dinverno & Foltz's 13F filing for Q3 2022, filed 25 Oct 2022.